Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...

Amgen’s Imdelltra, a bispecific T-cell engager (BiTE) that targets Delta-like canonical Notch ligand 3 (DLL3) and cluster of differentiation 3 (CD3) receptors, received US Food and Drug Administration ...

Glucocorticoids remain the first-line therapy. The current constrained pipeline features three emerging therapies: UPLIZNA (Amgen), obexelimab (Zenas BioPharma and Bristol Myers Squibb), and ...

Glucocorticoids remain the first-line therapy. The current constrained pipeline features three emerging therapies: UPLIZNA (Amgen), obexelimab (Zenas BioPharma and Bristol Myers Squibb), and ...

Supported by Amgen. Dr. Blackhall is supported by a grant (NIHR203308) from the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, by the NIHR Manchester ...

A Phase III trial with Amgen’s Nplate met its endpoint for efficacy in treating chemotherapy-associated thrombocytopaenia for GI cancer patients. Photo by Bloomberg/Bloomberg via Getty Images Amgen’s ...

May 30 (Reuters) - Amgen's (AMGN.O), opens new tab Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing a similar common and serious ...

Amgen (NASDAQ: AMGN) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this while most large-cap healthcare stocks struggle; yet it trades at just ...

With geopolitical and macroeconomic forces whipsawing markets, Alan Berro and his team at American Funds Washington Mutual are keeping their heads down and focusing on the “blocking and tackling ...